106771-59-9

Upstream product

• 4707-56-6 (2-(dimethylamino)phenyl)methanol 
• 10072-05-6 methyl 2-(dimethylamino)benzoate 
• 394-35-4 methyl 2-fluorobenzoate 

Downstream Products

• 157561-22-3 {2-[3-(2-Amino-ethyl)-indol-1-ylmethyl]-phenyl}-dimethyl-amine 
• 104340-38-7 2-[(1H-Benzimidazol-2-yl)thiomethyl]-N,N-dimethylbenzenamine 
• 128936-06-1 2-[(2-dimethylamino)benzylthio]imidazole 
• 123823-51-8 2-[(2-dimethylamino)benzylthio]-1-methylimidazole 
• 123823-57-4 2-[(2-dimethylamino)benzylthio]-1-phenylimidazole 
• 117347-99-6 Dimethyl-[2-(1-pyridin-2-yl-1H-imidazol-2-ylsulfanylmethyl)-phenyl]-amine 
• 1026882-42-7 [2-(1-Benzyl-1H-imidazol-2-ylsulfanylmethyl)-phenyl]-dimethyl-amine 
• 117347-98-5 Dimethyl-[2-(1-pyridin-2-ylmethyl-1H-imidazol-2-ylsulfanylmethyl)-phenyl]-amine 
• 117348-03-5 Dimethyl-[2-(1-pyridin-3-yl-1H-imidazol-2-ylsulfanylmethyl)-phenyl]-amine 
• 117348-02-4 1-(pyridin-4-yl)-2-(2-dimethylaminobenzylthio)imidazole 
• 1026493-25-3 Dimethyl-[2-(1-pyrimidin-2-yl-1H-imidazol-2-ylsulfanylmethyl)-phenyl]-amine 
• 117348-07-9 Dimethyl-{2-[1-(6-methyl-pyridin-2-yl)-1H-imidazol-2-ylsulfanylmethyl]-phenyl}-amine 
• 117348-01-3 Dimethyl-{2-[1-(5-methyl-pyridin-2-yl)-1H-imidazol-2-ylsulfanylmethyl]-phenyl}-amine 
• 117348-09-1 2-<<2-(dimethylamino)benzyl>thio>-1-<2-(3-methylpyridyl)>imidazole 

Relevant academic research and scientific papers

2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6- tetrahydrocyclopent[d]imidazoles as a novel class of gastric H+/K+-ATPase inhibitors

Substituted 2-sulfinylimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase. The 4,5-unsubstituted imidazole series 6-11 and the 1,4,5,6-tetrahydrocyclopent[d]imidazole series 12 were found to be potent inhibitors of the acid secretory enzyme H+/K+- ATPase. Structure-activity relationships indicate that the substitution of 2- pyridyl groups at the 1-position of the imidazole moiety combined with (2- aminobenzyl)sulfinyl groups at the 2-position leads to highly active compounds with a favorable chemical stability. Other substitution patterns in the imidazole moiety result in reducing biological activities. 2-[(2- Aminobenzyl)sulfinyl]-1-[2-(3-methylpyridyl)]-1,4,5,6- tetrahydrocyclopent[d]imidazole (12h, T-776) was selected for further development as a potential clinical candidate. Extensive study on the acid degradation of 12h indicates a mechanism of action different from that of omeprazole, the first H+/K+-ATPase inhibitor introduced to the market.

4(3H)-quinazolinone derivatives and pharmaceutical compositions

4(3H)-Quinazolinone derivatives of formula (I) are provided. STR1 wherein R1 is a hydrogen atom, a C1 -C6 alkyl group, an aryl group, a substituted aryl group, or an aralkyl group; R2 is a C1 -C6 alkylamino group, a phenyl group, a substituted phenyl group, or a 5- or 6-membered heterocyclic group containing one or more N, O or S as a hetero atom or atoms, said heterocyclic group optionally being substituted or fused with a benzene ring; n is 1 or 2; or R2 represents a geranyl group or a dipyridylmethyl group together with the group --(CH2)n --; and X is a hydrogen atom, a C1 -C6 alkyl group or a halogen atom, and pharmaceutically acceptable acid addition salts thereof. They are useful as antiulcer agents.